Sleep and Circadian Rhythm Disruption in Social Jetlag and Mental Illness - Progress in Molecular Biology and Translational Science - page 343

25. Martin JL, Jeste DV, Ancoli-Israel S. Older schizophrenia patients have more disrupted
sleep and circadian rhythms than age-matched comparison subjects. J Psychiatr Res .

2005;39(3):251-259.
26. Wulff K, Joyce E, Middleton B, Dijk DJ, Foster RG. The suitability of actigraphy, diary
data, and urinary melatonin profiles for quantitative assessment of sleep disturbances in
schizophrenia: a case report. Chronobiol Int . 2006;23(1-2):485-495.
27. Wulff K, Porcheret K, Cussans E, Foster RG. Sleep and circadian rhythm disturbances:
multiple genes and multiple phenotypes. Curr Opin Genet Dev . 2009;19(3):237-246.
28. Goldman M, Tandon R, DeQuardo JR, Taylor SF, Goodson J, McGrath M. Biological
predictors of 1-year outcome in schizophrenia in males and females. Schizophr Res .
1996;21(2):65-73.
29. Hofstetter JR, Lysaker PH, Mayeda AR. Quality of sleep in patients with schizophrenia
is associated with quality of life and coping. BMC Psychiatry . 2005;5:13.
30. Auslander LA, Jeste DV. Perceptions of problems and needs for service among middle-
aged and elderly outpatients with schizophrenia and related psychotic disorders. Commu-
nity Ment Health J . 2002;38(5):391-402.
31. Ehlers CL, Frank E, Kupfer DJ. Social zeitgebers and biological rhythms. A unified
approach to understanding the etiology of depression. Arch Gen Psychiatry . 1988;45
(10):948-952.
32. Chemerinski E, Ho BC, Flaum M, Arndt S, Fleming F, Andreasen NC. Insomnia as a
predictor for symptom worsening following antipsychotic withdrawal in schizophrenia.
Compr Psychiatry . 2002;43(5):393-396.
33. Gruber J, Miklowitz DJ, Harvey AG, et al. Sleep matters: sleep functioning and course of
illness in bipolar disorder. J Affect Disord . 2011;134(1-3):416-420.
34. Weinberger DR, Harrison PJ. Schizophrenia. 3rd ed. Oxford: Wiley-Blackwell; 2011.
35. Uhlhaas PJ, Singer W. Neural synchrony in brain disorders: relevance for cognitive dys-
functions and pathophysiology. Neuron . 2006;52(1):155-168.
36. Richardson G, Wang-Weigand S. Effects of long-term exposure to ramelteon, a mela-
tonin receptor agonist, on endocrine function in adults with chronic insomnia. Hum
Psychopharmacol . 2009;24(2):103-111.
37. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and
neurobiology. Biol Psychiatry . 2006;60(2):132-140.
38. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizo-
phrenia. Nat Rev Neurosci . 2008;9(6):437-452.
39. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to
schizophrenia. Am J Hum Genet . 2002;71(4):877-892.
40. Arguello PA, Gogos JA. A signaling pathway AKTing up in schizophrenia. J Clin Invest .
2008;118(6):2018-2021.
41. Brandon NJ, Sawa A. Linking neurodevelopmental and synaptic theories of mental ill-
ness through DISC1. Nat Rev Neurosci . 2011;12(12):707-722.
42. Johnstone M, Thomson PA, Hall J, McIntosh AM, Lawrie SM, Porteous DJ. DISC1 in
schizophrenia: genetic mouse models and human genomic imaging. Schizophr Bull .
2011;37(1):14-20.
43. Harrison PJ, Lyon L, Sartorius LJ, Burnet PW, Lane TA. The group II metabotropic
glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement
in schizophrenia. J Psychopharmacol . 2008;22(3):308-322.
44. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data
implicating the new human gene G72 and the gene for D-amino acid oxidase in schizo-
phrenia. Proc Natl Acad Sci USA . 2002;99(21):13675-13680.
45. Verrall L, Burnet PW, Betts JF, Harrison PJ. The neurobiology of D-amino acid oxidase
and its involvement in schizophrenia. Mol Psychiatry . 2010;15(2):122-137.